Conditions: Partial Epilepsy
Keywords: Partial Epilepsy Eslicarbazepine acetate Pharmacokinetics Tolerability
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 14
Healthy volunteers: yes

Brief summary:
This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to assess how these drugs are tolerated.

Detailed description:

Arms:
arm 1: Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9 arm 2: Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9

Interventions: intervention 1: Eslicarbazepine acetate intervention 2: Oxcarbazepine
Intervention descriptions: intervention 1: Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9 intervention 2: Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)

Protocol document: